Literature DB >> 18474721

Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study.

Katherine Oehlberg1, Frances K Barg, Gregory K Brown, Donna Taraborelli, Matthew B Stern, Daniel Weintraub.   

Abstract

Depression in Parkinson's disease (dPD) remains under recognized and under treated. As patients' beliefs may impact the reporting and treatment of depression, this study assessed the opinions of 38 dPD patients, approximately half with a self-reported poor response to antidepressant treatment, regarding the etiology and treatment of their depression using a semi-structured, audio-taped, qualitative interview. About half of the participants listed PD itself as a primary cause for their depressive symptoms, with most in this group citing psychosocial factors rather than PD-related neurobiological factors. Antidepressant therapy, psychotherapy, and self-initiated approaches were noted as preferred treatments for dPD. Many had concerns about antidepressant therapy, listing side-effects and medication dependency most frequently. About half raised concerns about psychotherapy with trust/discomfort, stigma, and transportation issues most frequently mentioned. This preliminary study suggests that many PD patients with clinically significant depressive symptoms attribute their depression to psychosocial factors and endorse nonpharmacologic treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474721      PMCID: PMC2680384          DOI: 10.1177/0891988708316862

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  18 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

Review 2.  Depression and Parkinson's disease: a review.

Authors:  J L Cummings
Journal:  Am J Psychiatry       Date:  1992-04       Impact factor: 18.112

Review 3.  Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease.

Authors:  J R Slaughter; K A Slaughter; D Nichols; S E Holmes; M P Martens
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

4.  "Pull yourself up by your bootstraps": a response to depression in older adults.

Authors:  Julia F Switzer; Marsha N Wittink; Brearley B Karsch; Frances K Barg
Journal:  Qual Health Res       Date:  2006-11

5.  What contributes to quality of life in patients with Parkinson's disease?

Authors:  A Schrag; M Jahanshahi; N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

6.  A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group.

Authors:  I H Richard; R Kurlan
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

Review 7.  Anxiety and Parkinson's disease.

Authors:  I H Richard; R B Schiffer; R Kurlan
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1996       Impact factor: 2.198

8.  Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.

Authors:  Daniel Weintraub; Paul J Moberg; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Am Geriatr Soc       Date:  2004-05       Impact factor: 5.562

9.  Recognition and treatment of depression in Parkinson's disease.

Authors:  Daniel Weintraub; Paul J Moberg; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-09       Impact factor: 2.680

10.  Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program.

Authors:  S M Sotsky; D R Glass; M T Shea; P A Pilkonis; J F Collins; I Elkin; J T Watkins; S D Imber; W R Leber; J Moyer
Journal:  Am J Psychiatry       Date:  1991-08       Impact factor: 18.112

View more
  19 in total

Review 1.  A systematic review and meta-analysis of cognitive behavioral and psychodynamic therapy for depression in Parkinson's disease patients.

Authors:  Cheng-Long Xie; Xiao-Dan Wang; Jie Chen; Hua-Zhen Lin; Yi-He Chen; Jia-Lin Pan; Wen-Wen Wang
Journal:  Neurol Sci       Date:  2015-02-28       Impact factor: 3.307

Review 2.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

Review 3.  Integrating Patient Concerns into Parkinson's Disease Management.

Authors:  Shen-Yang Lim; Ai Huey Tan; Susan H Fox; Andrew H Evans; Soon Chai Low
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 4.  The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

Authors:  Daniel Weintraub; Eugenia Mamikonyan
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-09       Impact factor: 4.105

5.  Barriers to mental health care utilization in Parkinson's disease.

Authors:  Roseanne D Dobkin; Jade Tiu Rubino; Jill Friedman; Lesley A Allen; Michael A Gara; Matthew Menza
Journal:  J Geriatr Psychiatry Neurol       Date:  2013-04-15       Impact factor: 2.680

6.  Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson's disease.

Authors:  Connie Veazey; Karon F Cook; Melinda Stanley; Eugene C Lai; Mark E Kunik
Journal:  J Clin Psychol Med Settings       Date:  2009-04-29

Review 7.  Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Authors:  Daniel Weintraub
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

8.  Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease.

Authors:  Danielle S Abraham; Thanh Phuong Pham Nguyen; Sean Hennessy; Shelly L Gray; Dawei Xie; Daniel Weintraub; Allison W Willis
Journal:  Am J Geriatr Psychiatry       Date:  2020-05-18       Impact factor: 4.105

9.  The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.

Authors:  Lin W Hung; Victor L Villemagne; Lesley Cheng; Nicki A Sherratt; Scott Ayton; Anthony R White; Peter J Crouch; SinChun Lim; Su Ling Leong; Simon Wilkins; Jessica George; Blaine R Roberts; Chi L L Pham; Xiang Liu; Francis C K Chiu; David M Shackleford; Andrew K Powell; Colin L Masters; Ashley I Bush; Graeme O'Keefe; Janetta G Culvenor; Roberto Cappai; Robert A Cherny; Paul S Donnelly; Andrew F Hill; David I Finkelstein; Kevin J Barnham
Journal:  J Exp Med       Date:  2012-04-02       Impact factor: 14.307

10.  Reformulating psychological difficulties in people with Parkinson's disease: the potential of a social relational approach to disablism.

Authors:  Jane Simpson; Helen McMillan; Donna Reeve
Journal:  Parkinsons Dis       Date:  2013-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.